直接作用型抗ウイルス薬の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Direct-acting Antiviral Drugs Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-15780 • 出版社/出版日：GlobalInfoResearch / 2020年7月28日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、107ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥504,600 (USD3,480)	▷ お問い合わせ
Multi User	￥756,900 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,009,200 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、直接作用型抗ウイルス薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。直接作用型抗ウイルス薬の種類別市場規模（NS3/4Aプロテアーゼ阻害剤、ヌクレオシド・ヌクレオチドNS5Bポリメラーゼ阻害剤、NS5A阻害剤、非ヌクレオシドNS5Bポリメラーゼ阻害剤）、用途別市場規模（病院、クリニック、外来手術センター、薬局、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：AbbVie Inc.、Bristol-Myers Squibb Company、Merck、GSK、Roche、Boehringer Ingelheim、Janssen (Johnson & Johnson)、Beximco Pharmaceuticals、Novartis、Gilead Sciences、Vertex Pharmaceuticals、Natco Pharma ・地域別グローバル市場分析 2015年-2020年 ・直接作用型抗ウイルス薬の北米市場（アメリカ、カナダ、メキシコ） ・直接作用型抗ウイルス薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・直接作用型抗ウイルス薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・直接作用型抗ウイルス薬の南米市場（ブラジル、アルゼンチン） ・直接作用型抗ウイルス薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：NS3/4Aプロテアーゼ阻害剤、ヌクレオシド・ヌクレオチドNS5Bポリメラーゼ阻害剤、NS5A阻害剤、非ヌクレオシドNS5Bポリメラーゼ阻害剤 ・用途別分析：病院、クリニック、外来手術センター、薬局、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The global Direct-acting Antiviral Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Direct-acting Antiviral Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Direct-acting Antiviral Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Direct-acting Antiviral Drugs market has been segmented into:
NS3/4A Protease Inhibitors
Nucleoside and Nucleotide NS5B Polymerase Inhibitors
NS5A Inhibitors
Non-Nucleoside NS5B Polymerase Inhibitors

By Application, Direct-acting Antiviral Drugs has been segmented into:
Hospitals
Clinics
Ambulatory Surgical Centers
Pharmacies
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Direct-acting Antiviral Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Direct-acting Antiviral Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Direct-acting Antiviral Drugs market.

The report offers in-depth assessment of the growth and other aspects of the Direct-acting Antiviral Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Direct-acting Antiviral Drugs Market Share Analysis
Direct-acting Antiviral Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Direct-acting Antiviral Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Direct-acting Antiviral Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Direct-acting Antiviral Drugs are:
AbbVie Inc.
Bristol-Myers Squibb Company
Merck
GSK
Roche
Boehringer Ingelheim
Janssen (Johnson & Johnson)
Beximco Pharmaceuticals
Novartis
Gilead Sciences
Vertex Pharmaceuticals
Natco Pharma

レポート目次

---

1 Direct-acting Antiviral Drugs Market Overview
1.1 Product Overview and Scope of Direct-acting Antiviral Drugs
1.2 Classification of Direct-acting Antiviral Drugs by Type
1.2.1 Global Direct-acting Antiviral Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Direct-acting Antiviral Drugs Revenue Market Share by Type in 2019
1.2.3 NS3/4A Protease Inhibitors
1.2.4 Nucleoside and Nucleotide NS5B Polymerase Inhibitors
1.2.5 NS5A Inhibitors
1.2.6 Non-Nucleoside NS5B Polymerase Inhibitors
1.3 Global Direct-acting Antiviral Drugs Market by Application
1.3.1 Overview: Global Direct-acting Antiviral Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Pharmacies
1.3.6 Others
1.4 Global Direct-acting Antiviral Drugs Market by Regions
1.4.1 Global Direct-acting Antiviral Drugs Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Direct-acting Antiviral Drugs (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Direct-acting Antiviral Drugs Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Direct-acting Antiviral Drugs Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Direct-acting Antiviral Drugs Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Direct-acting Antiviral Drugs Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Direct-acting Antiviral Drugs Status and Prospect (2015-2025)
2 Company Profiles
2.1 AbbVie Inc.
2.1.1 AbbVie Inc. Details
2.1.2 AbbVie Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AbbVie Inc. SWOT Analysis
2.1.4 AbbVie Inc. Product and Services
2.1.5 AbbVie Inc. Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.2 Bristol-Myers Squibb Company
2.2.1 Bristol-Myers Squibb Company Details
2.2.2 Bristol-Myers Squibb Company Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Bristol-Myers Squibb Company SWOT Analysis
2.2.4 Bristol-Myers Squibb Company Product and Services
2.2.5 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Merck SWOT Analysis
2.3.4 Merck Product and Services
2.3.5 Merck Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.4 GSK
2.4.1 GSK Details
2.4.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 GSK SWOT Analysis
2.4.4 GSK Product and Services
2.4.5 GSK Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.5 Roche
2.5.1 Roche Details
2.5.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Roche SWOT Analysis
2.5.4 Roche Product and Services
2.5.5 Roche Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Boehringer Ingelheim SWOT Analysis
2.6.4 Boehringer Ingelheim Product and Services
2.6.5 Boehringer Ingelheim Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.7 Janssen (Johnson & Johnson)
2.7.1 Janssen (Johnson & Johnson) Details
2.7.2 Janssen (Johnson & Johnson) Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Janssen (Johnson & Johnson) SWOT Analysis
2.7.4 Janssen (Johnson & Johnson) Product and Services
2.7.5 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.8 Beximco Pharmaceuticals
2.8.1 Beximco Pharmaceuticals Details
2.8.2 Beximco Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Beximco Pharmaceuticals SWOT Analysis
2.8.4 Beximco Pharmaceuticals Product and Services
2.8.5 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Novartis SWOT Analysis
2.9.4 Novartis Product and Services
2.9.5 Novartis Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.10 Gilead Sciences
2.10.1 Gilead Sciences Details
2.10.2 Gilead Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Gilead Sciences SWOT Analysis
2.10.4 Gilead Sciences Product and Services
2.10.5 Gilead Sciences Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.11 Vertex Pharmaceuticals
2.11.1 Vertex Pharmaceuticals Details
2.11.2 Vertex Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Vertex Pharmaceuticals SWOT Analysis
2.11.4 Vertex Pharmaceuticals Product and Services
2.11.5 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.12 Natco Pharma
2.12.1 Natco Pharma Details
2.12.2 Natco Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Natco Pharma SWOT Analysis
2.12.4 Natco Pharma Product and Services
2.12.5 Natco Pharma Direct-acting Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Direct-acting Antiviral Drugs Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Direct-acting Antiviral Drugs Players Market Share
3.2.2 Top 10 Direct-acting Antiviral Drugs Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Direct-acting Antiviral Drugs Revenue and Market Share by Regions
4.2 North America Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
4.3 Europe Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
4.5 South America Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
5 North America Direct-acting Antiviral Drugs Revenue by Countries
5.1 North America Direct-acting Antiviral Drugs Revenue by Countries (2015-2020)
5.2 USA Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
5.3 Canada Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
5.4 Mexico Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
6 Europe Direct-acting Antiviral Drugs Revenue by Countries
6.1 Europe Direct-acting Antiviral Drugs Revenue by Countries (2015-2020)
6.2 Germany Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
6.3 UK Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
6.4 France Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
6.5 Russia Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
6.6 Italy Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Direct-acting Antiviral Drugs Revenue by Countries
7.1 Asia-Pacific Direct-acting Antiviral Drugs Revenue by Countries (2015-2020)
7.2 China Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
7.3 Japan Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
7.4 Korea Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
7.5 India Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
8 South America Direct-acting Antiviral Drugs Revenue by Countries
8.1 South America Direct-acting Antiviral Drugs Revenue by Countries (2015-2020)
8.2 Brazil Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
8.3 Argentina Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Direct-acting Antiviral Drugs by Countries
9.1 Middle East & Africa Direct-acting Antiviral Drugs Revenue by Countries (2015-2020)
9.2 Saudi Arabia Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
9.3 UAE Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
9.4 Egypt Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
9.5 South Africa Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Direct-acting Antiviral Drugs Revenue and Market Share by Type (2015-2020)
10.2 Global Direct-acting Antiviral Drugs Market Forecast by Type (2019-2024)
10.3 NS3/4A Protease Inhibitors Revenue Growth Rate (2015-2025)
10.4 Nucleoside and Nucleotide NS5B Polymerase Inhibitors Revenue Growth Rate (2015-2025)
10.5 NS5A Inhibitors Revenue Growth Rate (2015-2025)
10.6 Non-Nucleoside NS5B Polymerase Inhibitors Revenue Growth Rate (2015-2025)
11 Global Direct-acting Antiviral Drugs Market Segment by Application
11.1 Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2015-2020)
11.2 Direct-acting Antiviral Drugs Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Ambulatory Surgical Centers Revenue Growth (2015-2020)
11.6 Pharmacies Revenue Growth (2015-2020)
11.7 Others Revenue Growth (2015-2020)
12 Global Direct-acting Antiviral Drugs Market Size Forecast (2021-2025)
12.1 Global Direct-acting Antiviral Drugs Market Size Forecast (2021-2025)
12.2 Global Direct-acting Antiviral Drugs Market Forecast by Regions (2021-2025)
12.3 North America Direct-acting Antiviral Drugs Revenue Market Forecast (2021-2025)
12.4 Europe Direct-acting Antiviral Drugs Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Direct-acting Antiviral Drugs Revenue Market Forecast (2021-2025)
12.6 South America Direct-acting Antiviral Drugs Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Direct-acting Antiviral Drugs Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global Direct-acting Antiviral Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Direct-acting Antiviral Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Direct-acting Antiviral Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Direct-acting Antiviral Drugs Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. AbbVie Inc. Corporate Information, Location and Competitors
Table 6. AbbVie Inc. Direct-acting Antiviral Drugs Major Business
Table 7. AbbVie Inc. Direct-acting Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 8. AbbVie Inc. SWOT Analysis
Table 9. AbbVie Inc. Direct-acting Antiviral Drugs Product and Solutions
Table 10. AbbVie Inc. Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Bristol-Myers Squibb Company Corporate Information, Location and Competitors
Table 12. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Major Business
Table 13. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Total Revenue (USD Million) (2018-2019)
Table 14. Bristol-Myers Squibb Company SWOT Analysis
Table 15. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product and Solutions
Table 16. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Merck Corporate Information, Location and Competitors
Table 18. Merck Direct-acting Antiviral Drugs Major Business
Table 19. Merck Direct-acting Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 20. Merck SWOT Analysis
Table 21. Merck Direct-acting Antiviral Drugs Product and Solutions
Table 22. Merck Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. GSK Corporate Information, Location and Competitors
Table 24. GSK Direct-acting Antiviral Drugs Major Business
Table 25. GSK Direct-acting Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 26. GSK SWOT Analysis
Table 27. GSK Direct-acting Antiviral Drugs Product and Solutions
Table 28. GSK Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Roche Corporate Information, Location and Competitors
Table 30. Roche Direct-acting Antiviral Drugs Major Business
Table 31. Roche Direct-acting Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 32. Roche SWOT Analysis
Table 33. Roche Direct-acting Antiviral Drugs Product and Solutions
Table 34. Roche Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Boehringer Ingelheim Corporate Information, Location and Competitors
Table 36. Boehringer Ingelheim Direct-acting Antiviral Drugs Major Business
Table 37. Boehringer Ingelheim Direct-acting Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 38. Boehringer Ingelheim SWOT Analysis
Table 39. Boehringer Ingelheim Direct-acting Antiviral Drugs Product and Solutions
Table 40. Boehringer Ingelheim Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Janssen (Johnson & Johnson) Corporate Information, Location and Competitors
Table 42. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Major Business
Table 43. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 44. Janssen (Johnson & Johnson) SWOT Analysis
Table 45. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Product and Solutions
Table 46. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Beximco Pharmaceuticals Corporate Information, Location and Competitors
Table 48. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Major Business
Table 49. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 50. Beximco Pharmaceuticals SWOT Analysis
Table 51. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product and Solutions
Table 52. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Novartis Corporate Information, Location and Competitors
Table 54. Novartis Direct-acting Antiviral Drugs Major Business
Table 55. Novartis Direct-acting Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 56. Novartis SWOT Analysis
Table 57. Novartis Direct-acting Antiviral Drugs Product and Solutions
Table 58. Novartis Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Gilead Sciences Corporate Information, Location and Competitors
Table 60. Gilead Sciences Direct-acting Antiviral Drugs Major Business
Table 61. Gilead Sciences Direct-acting Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 62. Gilead Sciences SWOT Analysis
Table 63. Gilead Sciences Direct-acting Antiviral Drugs Product and Solutions
Table 64. Gilead Sciences Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Vertex Pharmaceuticals Corporate Information, Location and Competitors
Table 66. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Major Business
Table 67. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 68. Vertex Pharmaceuticals SWOT Analysis
Table 69. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product and Solutions
Table 70. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Natco Pharma Corporate Information, Location and Competitors
Table 72. Natco Pharma Direct-acting Antiviral Drugs Major Business
Table 73. Natco Pharma Direct-acting Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 74. Natco Pharma SWOT Analysis
Table 75. Natco Pharma Direct-acting Antiviral Drugs Product and Solutions
Table 76. Natco Pharma Direct-acting Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Global Direct-acting Antiviral Drugs Revenue (Million USD) by Players (2015-2020)
Table 78. Global Direct-acting Antiviral Drugs Revenue Share by Players (2015-2020)
Table 79. Global Direct-acting Antiviral Drugs Revenue (Million USD) by Regions (2015-2020)
Table 80. Global Direct-acting Antiviral Drugs Revenue Market Share by Regions (2015-2020)
Table 81. North America Direct-acting Antiviral Drugs Revenue by Countries (2015-2020)
Table 82. North America Direct-acting Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Table 83. Europe Direct-acting Antiviral Drugs Revenue (Million USD) by Countries (2015-2020)
Table 84. Asia-Pacific Direct-acting Antiviral Drugs Revenue (Million USD) by Countries (2015-2020)
Table 85. South America Direct-acting Antiviral Drugs Revenue by Countries (2015-2020)
Table 86. South America Direct-acting Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Table 87. Middle East and Africa Direct-acting Antiviral Drugs Revenue (Million USD) by Countries (2015-2020)
Table 88. Middle East and Africa Direct-acting Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Table 89. Global Direct-acting Antiviral Drugs Revenue (Million USD) by Type (2015-2020)
Table 90. Global Direct-acting Antiviral Drugs Revenue Share by Type (2015-2020)
Table 91. Global Direct-acting Antiviral Drugs Revenue Forecast by Type (2021-2025)
Table 92. Global Direct-acting Antiviral Drugs Revenue by Application (2015-2020)
Table 93. Global Direct-acting Antiviral Drugs Revenue Share by Application (2015-2020)
Table 94. Global Direct-acting Antiviral Drugs Revenue Forecast by Application (2021-2025)
Table 95. Global Direct-acting Antiviral Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Direct-acting Antiviral Drugs Picture
Figure 2. Global Direct-acting Antiviral Drugs Revenue Market Share by Type in 2019
Figure 3. NS3/4A Protease Inhibitors Picture
Figure 4. Nucleoside and Nucleotide NS5B Polymerase Inhibitors Picture
Figure 5. NS5A Inhibitors Picture
Figure 6. Non-Nucleoside NS5B Polymerase Inhibitors Picture
Figure 7. Direct-acting Antiviral Drugs Revenue Market Share by Application in 2019
Figure 8. Hospitals Picture
Figure 9. Clinics Picture
Figure 10. Ambulatory Surgical Centers Picture
Figure 11. Pharmacies Picture
Figure 12. Others Picture
Figure 13. Global Direct-acting Antiviral Drugs Revenue (USD Million) and Growth Rate (2015-2025)
Figure 14. North America Direct-acting Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Europe Direct-acting Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Asia-Pacific Direct-acting Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. South America Direct-acting Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Middle East and Africa Direct-acting Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Direct-acting Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Direct-acting Antiviral Drugs Revenue Share by Players in 2019
Figure 21. Global Top 5 Players Direct-acting Antiviral Drugs Revenue Market Share in 2019
Figure 22. Global Top 10 Players Direct-acting Antiviral Drugs Revenue Market Share in 2019
Figure 23. Key Players Market Share Trend
Figure 24. Global Direct-acting Antiviral Drugs Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 25. Global Direct-acting Antiviral Drugs Revenue Market Share by Regions (2015-2020)
Figure 26. Global Direct-acting Antiviral Drugs Revenue Market Share by Regions in 2018
Figure 27. North America Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 28. Europe Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 29. Asia-Pacific Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 30. South America Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 31. Middle East and Africa Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 32. North America Direct-acting Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Figure 33. North America Direct-acting Antiviral Drugs Revenue Market Share by Countries in 2019
Figure 34. USA Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 35. Canada Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 36. Mexico Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 37. Europe Direct-acting Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Figure 38. Europe Direct-acting Antiviral Drugs Revenue Market Share by Countries in 2019
Figure 39. Germany Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 40. UK Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 41. France Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 42. Russia Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 43. Italy Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Direct-acting Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Figure 45. Asia-Pacific Direct-acting Antiviral Drugs Revenue Market Share by Countries in 2019
Figure 46. China Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 47. Japan Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 48. Korea Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 49. India Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 50. Southeast Asia Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 51. South America Direct-acting Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Figure 52. South America Direct-acting Antiviral Drugs Revenue Market Share by Countries in 2019
Figure 53. Brazil Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 54. Argentina Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 55. Middle East and Africa Direct-acting Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Figure 56. Middle East and Africa Direct-acting Antiviral Drugs Revenue Market Share by Countries in 2019
Figure 57. Saudi Arabia Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 58. UAE Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 59. Egypt Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 60. South Africa Direct-acting Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 61. Global Direct-acting Antiviral Drugs Revenue Share by Type (2015-2020)
Figure 62. Global Direct-acting Antiviral Drugs Revenue Share by Type in 2019
Figure 63. Global Direct-acting Antiviral Drugs Market Share Forecast by Type (2021-2025)
Figure 64. Global NS3/4A Protease Inhibitors Revenue Growth Rate (2015-2020)
Figure 65. Global Nucleoside and Nucleotide NS5B Polymerase Inhibitors Revenue Growth Rate (2015-2020)
Figure 66. Global NS5A Inhibitors Revenue Growth Rate (2015-2020)
Figure 67. Global Non-Nucleoside NS5B Polymerase Inhibitors Revenue Growth Rate (2015-2020)
Figure 68. Global Direct-acting Antiviral Drugs Revenue Share by Application (2015-2020)
Figure 69. Global Direct-acting Antiviral Drugs Revenue Share by Application in 2019
Figure 70. Global Direct-acting Antiviral Drugs Market Share Forecast by Application (2021-2025)
Figure 71. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 72. Global Clinics Revenue Growth Rate (2015-2020)
Figure 73. Global Ambulatory Surgical Centers Revenue Growth Rate (2015-2020)
Figure 74. Global Pharmacies Revenue Growth Rate (2015-2020)
Figure 75. Global Others Revenue Growth Rate (2015-2020)
Figure 76. Global Direct-acting Antiviral Drugs Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 77. Global Direct-acting Antiviral Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 78. Global Direct-acting Antiviral Drugs Revenue Market Share Forecast by Regions (2021-2025)
Figure 79. North America Direct-acting Antiviral Drugs Revenue Market Forecast (2021-2025)
Figure 80. Europe Direct-acting Antiviral Drugs Revenue Market Forecast (2021-2025)
Figure 81. Asia-Pacific Direct-acting Antiviral Drugs Revenue Market Forecast (2021-2025)
Figure 82. South America Direct-acting Antiviral Drugs Revenue Market Forecast (2021-2025)
Figure 83. Middle East and Africa Direct-acting Antiviral Drugs Revenue Market Forecast (2021-2025)
Figure 84. Sales Channel: Direct Channel vs Indirect Channel

---